Lin Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lin Feng has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Alvaro Manrique Garcia
2 shared publicationsKwangdeok Lee
2 shared publications- Andrea Grammatico
Medical Devices, Abbott , Plano, TX
1 shared publication Balbir Singh
1 shared publicationBertrand Pierre
1 shared publicationChristophe Leclercq
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Elsevier in JACC: Clinical Electrophysiology
Cardiac Resynchronization Therapy Using a Conduction System Pacing Defibrillation Lead in Patients Meeting CRT-D Indications
- 22 October 2026
- Published by Elsevier in JACC: Clinical Electrophysiology
Open AccessCardiac Resynchronization Therapy Using a Conduction System Pacing Defibrillation Lead in Patients Meeting CRT-D Indications
- Open Access
- 15 November 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (1) , 61-69
Atrial fibrillation detection performance of an insertable cardiac monitor: Results from an Assert-IQ post-market clinical study and a novel artificial intelligence algorithm
- 15 November 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (1) , 61-69
Open AccessAtrial fibrillation detection performance of an insertable cardiac monitor: Results from an Assert-IQ post-market clinical study and a novel artificial intelligence algorithm
- Open Access
- 1 January 2025
- Published by BMJ in Open Heart
- Vol. 12 (1) , e003242
Continuing evaluation of atrial fibrillation detection after cryptogenic stroke: 2-year findings from a multicentre study with Confirm Rx ICM
Background: The detection of atrial fibrillation (AF) after a cryptogenic stroke (CS) carries important therapeutic implications. In this study, we aimed to accurately assess the incidence of AF among CS subjects by using an insertable cardiac monitor (ICM). Methods: A prospective, single-arm, multicentre registry was conducted to identify AF in 155 CS subjects using the Confirm Rx ICM (Abbott, California, USA) across 20 global sites. Inclusion criteria comprised participants aged 40 years or older who had experienced CS within a 90-day window. At each follow-up visit, expert electrophysiologists reviewed and adjudicated ICM detected AF episodes. The primary endpoint was the cumulative incidence of true device-detected AF (lasting more than 30 s) at 6 months, evaluated with Kaplan-Meier methods. Results: AF incidence was 21.3% (95% CI 15.3% to 29.1%) at 6 months, increasing to 48.8% (95% CI 34.7% to 64.9%) at 24 months. Subjects with AF detection experienced an average of 50.9 true AF episodes per subject per year. The median time from implantation to AF detection (>30 s) was 72 days (IQR 7–261). Among subjects with 30 s AF detection, anticoagulation therapy was initiated in 65.2% (30/46) of subjects. Oral anticoagulation medication was prescribed in 8.3% (9/109) of subjects without AF. Recurrent ischaemic stroke or transient ischaemic attack occurred in 5 subjects (3.2%, 5/155). Conclusion: These results show that ICM-driven long-term continuous AF monitoring is associated with high diagnostic yield in CS subjects. Trial registration number: NCT03505801
- 1 January 2025
- Published by BMJ in Open Heart
- Vol. 12 (1) , e003242
Open AccessContinuing evaluation of atrial fibrillation detection after cryptogenic stroke: 2-year findings from a multicentre study with Confirm Rx ICM
Background: The detection of atrial fibrillation (AF) after a cryptogenic stroke (CS) carries important therapeutic implications. In this study, we aimed to accurately assess the incidence of AF among CS subjects by using an insertable cardiac monitor (ICM). Methods: A prospective, single-arm, multicentre registry was conducted to identify AF in 155 CS subjects using the Confirm Rx ICM (Abbott, California, USA) across 20 global sites. Inclusion criteria comprised participants aged 40 years or older who had experienced CS within a 90-day window. At each follow-up visit, expert electrophysiologists reviewed and adjudicated ICM detected AF episodes. The primary endpoint was the cumulative incidence of true device-detected AF (lasting more than 30 s) at 6 months, evaluated with Kaplan-Meier methods. Results: AF incidence was 21.3% (95% CI 15.3% to 29.1%) at 6 months, increasing to 48.8% (95% CI 34.7% to 64.9%) at 24 months. Subjects with AF detection experienced an average of 50.9 true AF episodes per subject per year. The median time from implantation to AF detection (>30 s) was 72 days (IQR 7–261). Among subjects with 30 s AF detection, anticoagulation therapy was initiated in 65.2% (30/46) of subjects. Oral anticoagulation medication was prescribed in 8.3% (9/109) of subjects without AF. Recurrent ischaemic stroke or transient ischaemic attack occurred in 5 subjects (3.2%, 5/155). Conclusion: These results show that ICM-driven long-term continuous AF monitoring is associated with high diagnostic yield in CS subjects. Trial registration number: NCT03505801